Medtronic plc (NYSE: MDT) said on 14 September 2026 it has launched an exchange offer to split off at least 80.1% of MiniMed Group, Inc. (Nasdaq: MMED), its diabetes technology unit.
The offer lets Medtronic shareholders swap their ordinary shares for MiniMed common stock at roughly a 7% discount, worth about $107.53 of MiniMed stock for every $100 of Medtronic stock tendered, in a transaction the companies said is structured to be generally tax-free for US federal income tax purposes.
How the MiniMed exchange offer works
Medtronic currently holds 252,813,348 shares of MiniMed common stock, close to 90% of the total outstanding, according to a release mirrored across financial news sites. MiniMed’s Form S-4 registration statement, filed with the Securities and Exchange Commission, covers up to 225,361,295 shares available for exchange.
Completion is conditioned on at least 112,680,647 MiniMed shares being issued in the swap, Medtronic said in its announcement. Goldman Sachs & Co. LLC and BofA Securities, Inc. are acting as dealer managers.
The offer is expected to expire on 9 October 2026, with the exchange ratio priced off volume-weighted average prices over 5-7 October, unless Medtronic extends the deadline. If the offer is undersubscribed, Medtronic has said it would complete the separation through a subsequent spin-off, split-off, or debt-for-equity exchange.
Second act of a phased separation
The exchange offer marks the latest step in a separation that began with MiniMed’s initial public offering, a $538m listing after which Medtronic retained roughly a 90% stake. MiniMed’s name itself is a revival: Medtronic’s diabetes unit traded under the MiniMed brand before a 2001 acquisition folded it into the wider group, and the company restored the name last year ahead of the split-off. MiniMed chief executive Que Dallara has described the exchange offer as the final stage of the separation from Medtronic, according to a company release.
Medtronic shares moved higher on the announcement, last changing hands at $94.08, up 3.68% on the day, against a 20-day range of $89.97 to $96.48. Trading volume ran below the 20-day average, at roughly 74% of typical levels. Short interest in the stock had climbed through early September, with FINRA’s daily short sale ratio rising from 0.326 on 28 August to 0.434 on 11 September, before easing back on the day of the announcement.
Medtronic’s underlying numbers
The exchange offer lands against a backdrop of steadily rising revenue at the parent company. Medtronic’s most recent 10-Q, covering the quarter ended 31 July 2026, reported revenue of $9.756bn and net income of $1.470bn, according to its filing with the SEC. That compares with revenue of $9.017bn and net income of $1.143bn in the prior quarter, ended 23 January 2026, and revenue of $8.961bn a quarter before that. Diluted earnings per share came in at $1.14 for the July quarter, up from $0.89 three months earlier and $1.07 in the quarter before that.
Looking back further, Medtronic’s revenue has grown in six of the past seven reported quarters, from $8.089bn in the quarter ended January 2024 to the latest $9.756bn figure, tracking a period in which the group has methodically carved out MiniMed as a standalone entity.
The corporate action also arrives alongside a firmer rate backdrop. The 10-year US Treasury yield stood at 4.95% on 10 September 2026, up from 4.83% previously, while the 2-year yield rose to 4.56% from 4.43%, according to Federal Reserve data. The yield curve, measured as the 10-year minus 2-year spread, narrowed slightly to 0.33 percentage points from 0.39, per the same source. Consumer prices rose to an index level of 334.131 in August from 332.813 the prior month, while unemployment held steady at 4.1%, according to Bureau of Labor Statistics data tracked by the Fed.
What happens next
Investors have until 9 October to decide whether to tender Medtronic shares into the offer at the built-in discount, or hold on and wait for Medtronic’s fallback route if the exchange falls short of its minimum threshold. Medtronic has said the pricing mechanism, based on volume-weighted average prices in the first week of October, will determine the final exchange ratio shareholders receive.
This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.
